Somewhat Positive Press Coverage Somewhat Unlikely to Affect C R Bard (BCR) Stock Price

Media stories about C R Bard (NYSE:BCR) have trended somewhat positive recently, Accern Sentiment reports. Accern scores the sentiment of news coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. C R Bard earned a news impact score of 0.07 on Accern’s scale. Accern also gave headlines about the medical instruments supplier an impact score of 45.5936292919565 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

BCR has been the topic of several research reports. Zacks Investment Research raised shares of C R Bard from a “hold” rating to a “buy” rating and set a $372.00 price target on the stock in a research note on Tuesday, December 26th. ValuEngine downgraded shares of C R Bard from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and one has given a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $320.83.

How to Become a New Pot Stock Millionaire

The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.37 and a current ratio of 1.72. C R Bard has a 52 week low of $223.02 and a 52 week high of $337.73. The company has a market capitalization of $24,140.00, a P/E ratio of 43.64, a PEG ratio of 2.53 and a beta of 0.52.

In other C R Bard news, VP John A. Deford sold 14,107 shares of C R Bard stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $333.48, for a total transaction of $4,704,402.36. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.80% of the stock is owned by insiders.

TRADEMARK VIOLATION NOTICE: This news story was posted by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.tickerreport.com/banking-finance/3272948/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-c-r-bard-bcr-stock-price.html.

About C R Bard

C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.

Insider Buying and Selling by Quarter for C R Bard (NYSE:BCR)

Receive News & Ratings for C R Bard Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C R Bard and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokers Offer Predictions for Regions Financial Co.’s FY2018 Earnings
Brokers Offer Predictions for Regions Financial Co.’s FY2018 Earnings
NewRiver  Receives Add Rating from Peel Hunt
NewRiver Receives Add Rating from Peel Hunt
Zumiez  Cut to “Hold” at BidaskClub
Zumiez Cut to “Hold” at BidaskClub
Dixons Carphone  Price Target Lowered to GBX 195 at HSBC
Dixons Carphone Price Target Lowered to GBX 195 at HSBC
Critical Comparison: Sonova  & Aradigm
Critical Comparison: Sonova & Aradigm
American Axle  versus Its Peers Critical Survey
American Axle versus Its Peers Critical Survey


© 2006-2018 Ticker Report. Google+.